Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | HTR1B | P28222 | 4/20 | 0.78 |
| ▸ | HTR6 | P50406 | 3/20 | 0.78 |
| ▸ | HTR2C | P28335 | 3/20 | 0.78 |
| ▸ | HTR1A | P08908 | 3/20 | 0.78 |
| ▸ | HTR1D | P28221 | 3/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.78 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.78 |
| ▸ | HTR7 | P34969 | 2/20 | 0.78 |
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.78 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.78 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.78 |
| ▸ | BLM | P54132 | 1/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.76 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.76 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.61 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29874859 | 1.00 | HTR2A (1.00) | HTR2AMEN1KMT2AHTR1BHTR6 | |
| SCHEMBL5023884 | 0.91 | HTR2A (0.83) | HTR2AMEN1KMT2AHTR1BHTR6 | |
| 5-Methoxytryptamine SCHEMBL41982 | 0.88 | HTR1A (1.00) | HTR2AMEN1KMT2AHTR1BHTR6 | |
| 5-Methoxytryptamine SCHEMBL29390103 | 0.88 | HTR1A (1.00) | HTR2AMEN1KMT2AHTR1BHTR6 | |
| 5-Methoxytryptamine SCHEMBL31109114 | 0.86 | NPSR1 (1.00) | HTR2AMEN1KMT2AHTR1BHTR6 | |
| 5-Methoxytryptamine SCHEMBL1322980 | 0.86 | NPSR1 (1.00) | HTR2AMEN1KMT2AHTR1BHTR6 | |
| 5-Methoxytryptamine SCHEMBL26617456 | 0.86 | HTR1A (0.97) | HTR2AMEN1KMT2AHTR1BHTR6 | |
| 5-Methoxytryptamine SCHEMBL130877 | 0.86 | HTR1A (0.97) | HTR2AMEN1KMT2AHTR1BHTR6 | |
| SCHEMBL13715395 | 0.86 | HTR2A (0.75) | HTR2AMEN1KMT2AHTR1BHTR6 | |
| SCHEMBL22185054 | 0.85 | HTR2A (0.73) | HTR2AMEN1KMT2AHTR1BHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117886642-A | Selenium-rich nutrient solution for tartary buckwheat production and application | 成都大学 | 2024-04-16 | — | — | CN | claimed |
| CN-115850269-A | Tetrahydro-beta-carboline compound and preparation method and application thereof | 南京工业大学 | 2023-03-28 | — | — | CN | claimed |
| CN-114984195-A | Novel application of fat membrane associated protein and related coding gene and fragment thereof | 上海中医药大学 | 2022-09-02 | — | — | CN | claimed |
| CN-110643032-B | Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance | 厦门赛诺邦格生物科技股份有限公司 | 2022-01-28 | — | — | CN | claimed |
| CN-112010838-B | Naphthalimide-indole derivative-based intracellular reticulum fluorescent probe and application thereof | 中国科学院化学研究所 | 2021-07-13 | — | — | CN | claimed |
| CN-112500412-A | Penamine A alkaloid structure simplification compound and application thereof | 中国人民解放军空军军医大学 | 2021-03-16 | — | — | CN | claimed |
| CN-112010838-A | Naphthalimide-indole derivative-based intracellular reticulum fluorescent probe and application thereof | 中国科学院化学研究所 | 2020-12-01 | — | — | CN | claimed |
| CN-106967213-B | Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance | 厦门赛诺邦格生物科技股份有限公司 | 2019-11-05 | — | — | CN | claimed |
| CN-106967213-A | Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance | 厦门赛诺邦格生物科技股份有限公司 | 2017-07-21 | — | — | CN | claimed |
| US-20160331725-A1 | USE OF COMPOUNDS THAT ARE ABLE TO INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASE STATES ASSOCIATED WITH A REDUCED IGF-1 SERUM LEVEL IN HUMANS AND ANIMALS | VEIJLEN N.V. | 2016-11-17 | — | — | US | claimed |
| WO-2005039546-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | VEIJLEN N.V. (AN) | 2005-05-06 | — | — | WO | claimed |
| US-6743791-B2 | ANTICANCER AGENTS; ANTIINFLAMMATORY AGENTS | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-01 | — | — | US | claimed |
| US-20030092714-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-15 | — | — | US | claimed |
| EP-0824544-B1 | PEPTIDYL COMPOUNDS WHICH INHIBIT METALLOPROTEINASE AND TNF LIBERATION AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LTD (GB) | 2003-04-16 | — | — | EP | claimed |
| EP-0566566-B1 | COMPOSITIONS AND METHODS FOR ALLEVIATING MENOPAUSAL SYMPTOMS | APPLIED MED RES LTD (US) | 1995-12-06 | — | — | EP | claimed |
| EP-0566566-A1 | COMPOSITIONS AND METHODS FOR ALLEVIATING MENOPAUSAL SYMPTOMS. | APPLIED MED RES LTD (US) | 1993-10-27 | — | — | EP | claimed |
| WO-1992011855-A1 | COMPOSITIONS AND METHODS FOR ALLEVIATING MENOPAUSAL SYMPTOMS | APPLIED MEDICAL RESEARCH, LTD. (US) | 1992-07-23 | — | — | WO | claimed |
| EP-0472628-A1 | USE OF MELATONIN DERIVATIVES FOR EFFECTING CONTRACEPTION | APPLIED MEDICAL RESEARCH, LTD. (US) | 1992-03-04 | — | — | EP | claimed |
| CN-1047974-A | Compositions and methods for effecting contraception | COHEN MICHAEL (NL) | 1990-12-26 | — | — | CN | claimed |
| WO-1990014084-A1 | USE OF MELATONIN DERIVATIVES FOR EFFECTING CONTRACEPTION | COHEN MICHAEL (NL) | 1990-11-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092714-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAP2K2 | HTR2A 2187/4885MEN1 3046/4885KMT2A 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.